Table II.

Subcutaneous growth of transfected or nontransfected B16 melanoma cells in DNA-vaccinated, syngeneic hosts

Group	Cells Transferred^a			Tumor Incidence^c
Group	Cell line	No. of cells	Mice Immune to^b	%	Tumor-bearing/ transplanted mice	Compare groups	p^d
1	B16.F10	10³	HBsAg (S)	70	7/10
2	B16.F10	10⁴	HBsAg (S)	100	10/10
3	B16.F10	10⁵	HBsAg (S)	100	10/10
4	B16.F10	10⁶	HBsAg (S)	100	10/10
5	B16.F10/S	10³	HBsAg (S)	10	1/10	5/1	0.019*
6	B16.F10/S	10⁴	HBsAg (S)	50	5/10	6/2	0.033*
7	B16.F10/S	10⁵	HBsAg (S)	60	6/10	7/3	0.087
8	B16.F10/S	10⁶	HBsAg (S)	50	5/10	8/4	0.033*
9	B16.F10	10³	T-Ag	60	6/10
10	B16.F10	10⁴	T-Ag	90	9/10
11	B16.F10	10⁵	T-Ag	100	10/10
12	B16.F10	10⁶	T-Ag	100	10/10
13	B16.F10/T	10³	T-Ag	0	0/10	13/9	0.0104*
14	B16.F10/T	10⁴	T-Ag	0	0/10	14/10	0.0001*
15	B16.F10/T	10⁵	T-Ag	0	0/10	15/11	< 0.0001*
16	B16.F10/T	10⁶	T-Ag	40	4/10	16/12	0.0006*

a Nontransfected B16 cells (B16.F10) or B16 cells transfected with HBsAg-encoding BMG/HBS plasmid DNA (B16.F10/S) or T-Ag-encoding vector BMG/T-Ag.1 plasmid DNA (B16.F10/T) were transplanted into C57BL/6 mice; 10³, 10⁴, 10⁵, or 10⁶ cells suspended in 0.05 ml PBS were injected s.c. into the left lateral flank.
b All mice were injected intramuscularly with 100 μg of plasmid DNA 3 wk before the s.c. tumor cell transplantation. Mice were injected with either pCI/S vector DNA (mice immune to HBsAg or S (small HBsAg)), or pCMV/T vector DNA (mice immune to T-Ag).
c Tumor growth was monitored every second or third day. The percentage (%) of mice developing a tumor and the number of tumor-bearing mice/total number of transplanted mice are listed. The data in this table and in Figure 9 are from the same experiment.
d p values were calculated using Fisher’s exact test; *, statistically significant.